At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 87 enrolled
Drug / intervention
SOF/VEL +1 moredrug
Likely dose
SOF/VEL 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic HCV Infection
In Brief
A Phase 3 clinical trial evaluating SOF/VEL and SOF/VEL/VOX for Hepatitis C Virus Infection. Completed, enrolled 87 participants across 22 sites.
Detailed Summary
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of therapy with Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC in participants with chronic HCV infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus Infection
CountriesSouth Korea
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartJan 2020
Primary CompletionNov 2020
TodayJul 2026
First PostedDec 26, 2019
Enrollment StartJan 3, 2020
Primary CompletionNov 12, 2020
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.5 years ago
Interventions
SOF/VELdrug
400/100 mg FDC tablet orally once daily.
SOF/VEL/VOXdrug
400/100/100 mg FDC tablet orally once daily.